行情

ABEO

ABEO

Abeona
NASDAQ

实时行情|Nasdaq Last Sale

2.260
-0.175
-7.19%
盘后: 2.260 0 0.00% 16:34 10/17 EDT
开盘
2.390
昨收
2.435
最高
2.500
最低
2.210
成交量
72.48万
成交额
--
52周最高
10.41
52周最低
1.460
市值
1.11亿
市盈率(TTM)
-1.4255
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ABEO 新闻

  • 菲律宾拟对电子烟大幅加税
  • 新浪财经.1小时前
  • 沙特阿美:IPO时机将取决于市场条件和股东
  • 新浪财经.2小时前
  • 如何投资红利ETF:耐心比择时更重要么?
  • 新浪财经.2小时前
  • 易纲会见美联储主席鲍威尔 交换了对货币政策等看法
  • 央行.2小时前

更多

所属板块

生物技术和医学研究
+0.95%
制药与医学研究
+0.61%

热门股票

名称
价格
涨跌幅

ABEO 简况

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
展开

Webull提供Abeona Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。